Cros

Data Shows 50% of New Trials Have Sites in Asia Pacific

Retrieved on: 
Thursday, December 15, 2022
Row, Best practice, Gene, Aerospace Journalist of the Year Awards, Cros, Cell, Data management, Frost, GlobalData, Drug development, III, NDA, Growth, Research, US FDA, Fine chemical, Pharmaceutical industry, Medical device, Risk management, EU, IND

SINGAPORE, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Novotech, the Asia Pacific centered biotech specialist CRO said the latest industry research publication by GlobalData and Novotech found almost 50% of new trials had sites in Asia Pacific.

Key Points: 
  • SINGAPORE, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Novotech, the Asia Pacific centered biotech specialist CRO said the latest industry research publication by GlobalData and Novotech found almost 50% of new trials had sites in Asia Pacific.
  • According to the new publication titled State of the Global Biotech Landscape: Where the Opportunities Lie, demand for Asia Pacific trial sites is strong with almost half of the more than 27,000 clinical trials initiated in 2021 having sites in Asia Pacific.
  • The data shows almost 12,900 of the new trials had sites in Asia Pacific.
  • Phases I and II were dominated by Asia Pacific, which served as a trial location in 57% and 49% of trials, respectively.

Parexel Teams with MyEyeDr. to Increase Patient Access and Participation in Ophthalmology Clinical Trials

Retrieved on: 
Thursday, December 15, 2022
Macular degeneration, Ophthalmology, LP, Clinical trial, Parexel, Cros, Ecosystem, Practice management, Doctor of Philosophy, Dignity, Endocrinology, Diabetic retinopathy, CVS, Optometry, Patient, Pharmaceutical industry

are currently collaborating on recruitment for a diabetic retinopathy clinical trial with future plans to expand into additional therapeutic areas such as endocrinology.

Key Points: 
  • are currently collaborating on recruitment for a diabetic retinopathy clinical trial with future plans to expand into additional therapeutic areas such as endocrinology.
  • “Meeting patients where they already are — such as centers providing annual routine eye exams and other vision care — is vital to the development of new therapies,” said Clare Grace, PhD, Chief Patient Officer for Parexel.
  • will partner on recruitment of patients for a wide variety of ophthalmology indications, including Macular Degeneration, one of the leading causes of visual disability worldwide.
  • Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster.

Velocity Clinical Research acquires Meridian Clinical Research creating largest global research sites business

Retrieved on: 
Thursday, December 15, 2022
Acquisition, COVID-19 vaccine, Cros, Running, Biotechnology, Ice, Drug development, Multiple sclerosis, III, Research, Database, Acne, COVID-19, Patient, Fine chemical, Pharmaceutical industry, Medical imaging, Meridian, Velocity

DURHAM, N.C., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Velocity Clinical Research (“Velocity”), the leading integrated research site organization, today announces its acquisition of Meridian Clinical Research for an undisclosed amount.

Key Points: 
  • DURHAM, N.C., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Velocity Clinical Research (“Velocity”), the leading integrated research site organization, today announces its acquisition of Meridian Clinical Research for an undisclosed amount.
  • As a result of this acquisition, Velocity will have sites in 25 U.S. states, employing over 1500 clinical research professionals.
  • Consequently, Sponsors and Clinical Research Organizations (CRO) have additional foresight and planning time to resource, activate, recruit and deliver clinical trials.
  • Meridian's principal investigators are deeply engaged in clinical research, and every research site is staffed by highly trained research personnel.

Clinical ink Selected for Global Late Phase Parkinson’s Disease Programs

Retrieved on: 
Wednesday, December 14, 2022
Movement, Diagnosis, Drug discovery, Human, Movement disorders, MDS, Guest appearance, Cros, Moca, Critical path, Clinical, Research, Biomarker, PGI, Patient, CGI, Medical imaging

This late-phase clinical development program follows patients over the course of eighteen months and aims to identify measures that can detect Parkinson’s disease progression before the onset of significant symptoms.

Key Points: 
  • This late-phase clinical development program follows patients over the course of eighteen months and aims to identify measures that can detect Parkinson’s disease progression before the onset of significant symptoms.
  • By adopting Clinical ink’s BrainBaselineä platform, researchers are now able to access essential insights into Parkinson’s disease progression via remotely monitored sensor biometrics and wearable data collected passively and during fit-for-purpose active tasks.
  • Clinical ink is the global life science company that brings data, technology, and patient science together.
  • By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.

Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings

Retrieved on: 
Thursday, December 8, 2022
CO, DSA, Pharmacology, Marie Cassidy, Marketing, Cros, DVM, Toxicology, Pathology, Therapy, Pharmaceutical industry, Medical imaging, MD

These openings and expansions reflect the Company’s ongoing initiatives to broaden its portfolio of pre-clinical and clinical service offerings.

Key Points: 
  • These openings and expansions reflect the Company’s ongoing initiatives to broaden its portfolio of pre-clinical and clinical service offerings.
  • The center of excellence will support the entire spectrum of biotherapeutic drug development, from early-stage discovery to clinical trials.
  • In addition to the bioanalytical and biomarker services, the site will offer customized solutions for novel modalities including cell and gene therapy products, further broadening Inotiv’s preclinical service offerings.
  • Finally, the Company has completed the expansion of its Boulder, CO, facility, resulting in approximately 30% additional capacity to support its discovery pharmacology and histopathology offerings.

Proteomics labs worldwide can now access SomaLogic’s industry-leading 7,000-plex SomaScan® Assay with the Certified Site program

Retrieved on: 
Wednesday, December 7, 2022
EDTA, SomaLogic, Annual report, Epitope, Washington University in St. Louis, Security (finance), Beth Israel Deaconess Medical Center, Proteomics, Cros, CVS, Urine, Research, Plasma, Fine chemical, Risk management

By becoming a SomaLogic Certified Site, labs can run assays on SomaLogic’s SomaScan® Platform—the largest commercially available proteomics platform—and accelerate their own research and generate revenue as a service provider.

Key Points: 
  • By becoming a SomaLogic Certified Site, labs can run assays on SomaLogic’s SomaScan® Platform—the largest commercially available proteomics platform—and accelerate their own research and generate revenue as a service provider.
  • “The Certified Sites program allows us to expand the availability of our platform to labs and institutions around the world,” said Executive Vice President of SomaLogic’s Life Sciences business, Adam Taich.
  • SomaLogic launched the Certified Site program with labs at the National Institutes of Health, Washington University and Beth Israel Deaconess Medical Center.
  • In November, Molecular Genomics in Singapore became the first site in Asia to offer the 7,000-plex SomaScan® Assay and provide SomaScan data to their customers.

Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials

Retrieved on: 
Monday, December 5, 2022
Best practice, Gene, Aerospace Journalist of the Year Awards, Cros, Cell, Data management, Frost, Drug development, NDA, Research, US FDA, Risk management, Pharmaceutical industry, IND

SINGAPORE, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Novotech, the leading Asia Pacific biotech specialist CRO, has been awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacific contract research organization industry.

Key Points: 
  • SINGAPORE, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Novotech, the leading Asia Pacific biotech specialist CRO, has been awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacific contract research organization industry.
  • Novotech has been a recipient of the Frost & Sullivan Asia Pacific Best Practices awards since 2006.
  • “Our approach involves the deployment of best practices and strategic analytics across a value chain.
  • In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions delivering exclusive benefits for sponsors.

Outlook on the Glycomics Global Market to 2029 - Rising R&D Investment by Biotechnology Companies for Novel Drug Development Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, December 16, 2022
Biotechnology, Pharmaceutical, Health, Glycomics, Enzyme, Diagnosis, Drug discovery, Government, Proteomics, Hospital, Cros, Cancer, Biotechnology, Drug development, Growth, Research, Investment, Policy, Therapy, Fine chemical

Rising R&D investment by biotechnology companies for novel drug development is a key driver for the growth of the global glycomics market.

Key Points: 
  • Rising R&D investment by biotechnology companies for novel drug development is a key driver for the growth of the global glycomics market.
  • This is attributed to the recurrent application of in discovery of novel drugs and diagnostic testing coupled with re-purchases, worldwide.
  • The biopharmaceutical & biotechnology companies segment accounted for the highest revenue in 2021 and is projected to maintain its dominance over the forecast period.
  • Rising R&D investment by public and private investors is a key factor that is expected to drive the segment growth.

Global Cell and Gene Therapy CRO Market Trends and Forecasts Report 2022-2035: How is the Research and Development (R&D) Activity Evolving in the Cell and Gene Therapy Industry? - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 14, 2022
Biotechnology, Pharmaceutical, Genetics, Health, SOP, Gene, PPD, Food, R, ATMP, ICON, IND, CMIC, QPS, Research, Geography, Cell, FDA, Cros, Investment, Genetic engineering, Growth, Area, Food and Drug Administration Safety and Innovation Act, Marketing, Creative Biolabs, Syneos Health, LabCorp, USD, Medicine, Fine chemical, Antibiotics, Pharmaceutical industry, Vaccine, Evotec, IQVIA

The "Cell and Gene Therapy CROs Market (3rd Edition), 2022-2035" report features an extensive study of the current market landscape and future potential of the cell and gene therapy CROs market, over the next decade.

Key Points: 
  • The "Cell and Gene Therapy CROs Market (3rd Edition), 2022-2035" report features an extensive study of the current market landscape and future potential of the cell and gene therapy CROs market, over the next decade.
  • How is the research and development (R&D) activity evolving in the cell and gene therapy industry?
  • What is the need for contract research organizations (CROs) in the cell and gene therapy domain?
  • Who are the key players engaged in the cell and gene therapy CROs market?

20/20 Onsite Shines a Spotlight on Another One-of-a-kind Delivery Model for Clinical Trials: Mobile Vision Pods

Retrieved on: 
Tuesday, December 13, 2022
Other Health, Health, Practice Management, Optical, Managed Care, Travel, Hotel manager, School, ASP.NET MVC, Patient, Cros, MVC, MVP, MVP Model 3, Clinical trial, Arbutus Biopharma, MCS, Medical imaging, Onshore

20/20 Onsite, a Boston-based mobile optometry company, has expanded its clinical research program with a one-of-a-kind delivery model to make clinical trials even more accessible for patients across the country.

Key Points: 
  • 20/20 Onsite, a Boston-based mobile optometry company, has expanded its clinical research program with a one-of-a-kind delivery model to make clinical trials even more accessible for patients across the country.
  • The model, called Mobile Vision Pods (MVP), utilizes a modular structure, making it an ideal solution for clinical researchers who need a temporary but full-service site to accommodate intense patient visit schedules.
  • The MVP is the natural midway point between us coming inside in the Mobile Clinical Suite, and us being outside in the Mobile Vision Clinic,'' says Vice President of Life Sciences Jess Mays.
  • These pods have the look and feel of a brick-and-mortar clinic, while still having the mobility and flexibility of our MVC.